The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 701–800 of 1,000
Rituximab for treatment of ocular inflammatory disease: a series of four cases
Kurz, P. A., Suhler, E. B., Choi, D., & Rosenbaum, J. T. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.133173 · Cited by 59
Das, M., Lü, J., Joseph, M., Aggarwal, R., Kanji, S., McMichael, B., Lee, B. S., Agarwal, S., Ray‐Chaudhury, A., Iwenofu, O. H., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412798889090 · Cited by 59
Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis
Bajpai, M., Chopra, P., Dastidar, S. G., & Ray, A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.641 · Cited by 59
Heiligenhaus, A., THURAU, S. R., Hennig, M., Grajewski, R. S., & Wildner, G. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1485-8 · Cited by 59
Current and future perspectives in the management of juvenile idiopathic arthritis
Ruperto, N., & Martini, A. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30034-8 · Cited by 59
Silverman, G. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22020 · Cited by 59
Successful treatment of refractory adult onset Still's disease with rituximab
Ahmadi-Simab, K., Lamprecht, P., Jankowiak, C., & Gross, W. L. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.047621 · Cited by 59
Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004).
Scheinberg, M. A., Hamerschlak, N., Kutner, J. M., Ribeiro, A. A. F., Ferreira, E., Goldenberg, J., Kiss, M. H. B., & Chahade, W. H. (2006) · PubMed · Cited by 59
Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis
Mousavi, M. J., Jamshidi, A., Chopra, A., Aslani, S., Akhlaghi, M., & Mahmoudi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26911 · Cited by 58
Effects of different B-cell-depleting strategies on the lymphatic tissue
Tur, C., Eckstein, M., Bucci, L., Auth, J., Bergmann, C., Rauber, S., Hagen, M., Nöthling, D.-M., Boeltz, S., Wirsching, A., et al. (2025) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2025.06.2120 · Cited by 64
Brenner, M., Meng, H.-C., Yarlett, N. C., Joe, B., Griffiths, M. M., Remmers, E. F., Wilder, R. L., & Gulko, P. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7894 · Cited by 57
B cell biology: implications for treatment of systemic lupus erythematosus
Anolik, J. H. (2013) · Lupus · doi:10.1177/0961203312471576 · Cited by 58
Rituximab mediates loss of CD19 on B cells in the absence of cell death
Jones, J. D. G., Hamilton, B. J., & Rigby, W. F. C. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34560 · Cited by 58
Cogan's Syndrome—Clinical Guidelines and Novel Therapeutic Approaches
Tayer-Shifman, O. E., Ilan, O., Tovi, H., & Tal, Y. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8406-7 · Cited by 58
Berglund, Å., Willén, L., Grödeberg, L., Skattum, L., Hagberg, H., & Pauksens, K. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.914243 · Cited by 58
Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome
Santis, M. D., Straface, G., Cavaliere, A. F., Carducci, B., & Caruso, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030254 · Cited by 58
Lin, W. Y., Gong, Q., Seshasayee, D., Lin, Z., Ou, Q., Ye, S., Suto, E., Shu, J., Lee, W. P., Lee, C. V., et al. (2007) · Blood · doi:10.1182/blood-2007-04-088088 · Cited by 58
Celastrol suppresses humoral immune responses and autoimmunity by targeting the COMMD3/8 complex
Shirai, T., Nakai, A., Ando, E., Fujimoto, J., Leach, S., Arimori, T., Higo, D., van Eerden, F. J., Tulyeu, J., Liu, Y., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adc9324 · Cited by 59
Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens
Koning, F., Thomas, R., Rossjohn, J., & Toes, R. E. M. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.59 · Cited by 57
Levesque, M. C. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03979.x · Cited by 57
Ma, L., Qin, J., Ji, H., Zhao, P., & Jiang, Y. (2013) · Liver International · doi:10.1111/liv.12245 · Cited by 59
Inhibitor eradication with rituximab in haemophilia: where do we stand?
Franchini, M., & Mannucci, P. M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12829 · Cited by 58
Catalán, D., Aravena, O., Sabugo, F., Wurmann, P., Soto, L., Kalergis, A. M., Cuchacovich, M., Aguillón, J. C., & P-07-088-F, M. N. O. I. A. I. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2985 · Cited by 56
The Function of MicroRNAs in B-Cell Development, Lymphoma, and Their Potential in Clinical Practice
Zheng, B., Xi, Z., Liu, R., Yin, W., Sui, Z., Ren, B., Miller, H. E., Gong, Q., & Liu, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00936 · Cited by 60
Rivellese, F., Humby, F., Bugatti, S., Fossati‐Jimack, L., Rizvi, H., Lucchesi, D., Lliso-Ribera, G., Nerviani, A., Hands, R., Giorli, G., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41184 · Cited by 57
Efficacy of low-dose rituximab for mixed cryoglobulinemia
Visentini, M., Granata, M., Veneziano, M. L., Borghese, F., Carlesimo, M., Pimpinelli, F., Fiorilli, M., & Casato, M. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.06.008 · Cited by 57
Rituximab Removes Intrarenal B Cell Clusters in Patients With Renal Vascular Allograft Rejection
Steinmetz, O. M., Lange-Hüsken, F., Turner, J., Vernauer, A., Helmchen, U. M., Stahl, R. A. K., Thaiss, F., & Panzer, U. (2007) · Transplantation · doi:10.1097/01.tp.0000282786.58754.2b · Cited by 57
The need for new classification criteria for rheumatoid arthritis
Aletaha, D., Breedveld, F. C., & Smolen, J. S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21410 · Cited by 57
Epratuzumab in the therapy of oncological and immunological diseases
Goldenberg, D. M. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.10.1341 · Cited by 57
Effects of B cell–activating factor on tumor immunity
Yarchoan, M. M., Ho, W. J., Mohan, A. A., Shah, Y., Vithayathil, T., Leatherman, J. M., Dennison, L., Zaidi, N., Ganguly, S., Woolman, S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136417 · Cited by 56
Follicular dendritic cells: origin, function, and different disease-associated patterns
Rezk, S. A., Nathwani, B. N., Zhao, X., & Weiss, L. M. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.10.005 · Cited by 56
A perspective on B-cell-targeting therapy for SLE
Looney, R. J., Anolik, J. H., & Sanz, I. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0213-x · Cited by 60
Stohl, W., Gómez-Reino, J. J., Olech, E., Dudler, J., Fleischmann, R., Zerbini, C. A. F., Ashrafzadeh, A., Grzeschik, S. M., Bieraugel, R., Green, J., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200706 · Cited by 56
Rituximab as a Treatment Option for Refractory Endogenous Anterior Uveitis
Tappeiner, C., Heinz, C., Specker, C., & Heiligenhaus, A. (2007) · Ophthalmic Research · doi:10.1159/000103239 · Cited by 56
Park, W., Majstorović, L. B., Milaković, D., Kasay, A. B., El-Khouri, E. C., Irazoque-Palazuelos, F. C., Cons-Molina, F., Shesternya, P. A., Miranda, P., Medina-Rodriguez, F. G., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1487912 · Cited by 55
Pollastro, S., Klarenbeek, P. L., Doorenspleet, M. E., van Schaik, B. D. C., Esveldt, R. E., Thurlings, R. M., Boumans, M. J. H., Gerlag, D. M., Tak, P. P., Vos, K., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214898 · Cited by 55
Deshmukh, R. (2023) · Materials Today Communications · doi:10.1016/j.mtcomm.2023.105877 · Cited by 64
Hegedűs, L. D., Smith, T. J., Douglas, R. S., & Nielsen, C. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03806.x · Cited by 55
Therapeutic effects of TACI-Ig on rat with adjuvant arthritis
Wang, D., Chang, Y.-W., Wu, Y. R., Zhang, L., Yan, S., Xie, G., Qin, Q., Jin, J., Wang, W.-J., Fang, J., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04293.x · Cited by 55
Sellam, J., Rouanet, S., Hendel, H., Miceli‐Richard, C., Combe, B. G., Sibilia, J., Loët, X. L., Tebib, J. G., Jourdan, R., Dougados, M., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38023 · Cited by 55
Orme, M., MacGilchrist, K., Mitchell, S., Spurden, D., & Bird, A. (2012) · Biologics : Targets & Therapy · doi:10.2147/btt.s36707 · Cited by 416
Vosslamber, S., Raterman, H. G., Kraan, T. C. T. M. V. D. P., Schreurs, M. W. J., Blomberg, B. M. E. V., Nurmohamed, M. T., Lems, W. F., Dijkmans, B. A. C., Voskuyl, A. E., & Verweij, C. L. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.147199 · Cited by 55
Avillach, C., Tran, A., Moulin, B., Choukroun, G. J., Gatault, P., Courivaud, C., Augusto, J., Ficheux, M., Vigneau, C. M., Thervet, É., et al. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw101 · Cited by 55
Fc Receptors as Adaptive Immunoreceptors
Daëron, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_7 · Cited by 55
Devauchelle‐Pensec, V., Cagnard, N., Pers, J., Youinou, P., Saraux, A., & Chiocchia, G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27509 · Cited by 55
Carter, R. H. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.3.377 · Cited by 57
What should be our treatment goal in rheumatoid arthritis today?
Js, S., & Aletaha, D. (2006) · PubMed · Cited by 55
Wang, E., Kawaoka, S., Roe, J.-S., Shi, J., Hohmann, A. F., Xu, Y., Bhagwat, A. S., Suzuki, Y., Kinney, J. B., & Vakoc, C. R. (2015) · eLife · doi:10.7554/elife.06377 · Cited by 54
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease (Coiffier et al., 2002; Edwards et al., 2004).”
BackgroundBedside to bench: defining the immunopathogenesis of psoriatic arthritis
Bravo, A., & Kavanaugh, A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0285-8 · Cited by 54
Simón, D., Taşçılar, K., Schmidt, K. G., Manger, B., Weckwerth, L., Sokolova, M. V., Bucci, L., Fagni, F., Manger, K., Schuch, F., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41914 · Cited by 59
A simple, economic, time‐resolved killing assay
Kummerow, C., Schwarz, E. C., Bufe, B., Zufall, F., Hoth, M., & Qu, B. (2014) · European Journal of Immunology · doi:10.1002/eji.201444518 · Cited by 54
What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?
Culshaw, S., McInnes, I. B., & Liew, F. Y. (2011) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2010.01669.x · Cited by 55
Zojer, N., Kirchbacher, K., Vesely, M., Hübl, W., & Ludwig, H. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600564803 · Cited by 54
Rigby, W. F. C., Ferraccioli, G., Greenwald, M., Montiel, B. E. Z., Fleischmann, R., Wassenberg, S., Ogale, S. S., Armstrong, G., Jahreis, A., Burke, L. S., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20419 · Cited by 54
Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis
Möller, B., Aeberli, D., Eggli, S., Fuhrer, M., Vajtai, I., Vögelin, E., Ziswiler, H., Dahinden, C. A., & Villiger, P. M. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2686 · Cited by 54
Anti-CD20 monoclonal antibodies: Beyond B-cells
Avivi, I. M., Stroopinsky, D., & Katz, T. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.002 · Cited by 54
Egwuagu, C. E., & Yu, C. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2015012558 · Cited by 57
Emery, P., Mease, P. J., Rubbert‐Roth, A., Curtis, J. R., Müller‐Ladner, U., GAYLIS, N. B., Williams, S., Reynard, M., & Tyrrell, H. E. J. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker253 · Cited by 54
Self-citationIntracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity
Taher, T. E. I., Byström, J., Ong, V. H., Isenberg, D. A., Renaudineau, Y., Abraham, D., & Mageed, R. A. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8609-4 · Cited by 57
Bayer, G., Agier, M., Lioger, B., Lepelley, M., Zénut, M., Lanoue, M.-C., Maillot, F., & Jonville‐Béra, A. ‐. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.06.009 · Cited by 54
B cells in rheumatoid synovitis.
Weyand, C. M., Seyler, T. M., & Goronzy, J. J. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1737 · Cited by 54
Immune therapies of autoimmune diseases: are we approaching a real cure?
Chatenoud, L. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.004 · Cited by 52
Biologics in children’s autoimmune disorders: efficacy and safety
Breda, L., Torto, M. D., Sanctis, S. D., & Chiarelli, F. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-010-1238-z · Cited by 52
Emerging biologic drugs for the treatment of rheumatoid arthritis
Puppo, F., Murdaca, G., Ghio, M., & Indiveri, F. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.04.016 · Cited by 53
Teitsma, X., Marijnissen, A., Bijlsma, J., Lafeber, F., & Jacobs, J. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1108-9 · Cited by 52
Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab
Davoudi, S., Ebrahimiadib, N., Yasa, C., Sevgi, D. D., Roohipoor, R., Papavasilieou, E., Comander, J., & Sobrin, L. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.04.019 · Cited by 53
Kaegi, C., Wuest, B., Crowley, C., & Boyman, O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788830 · Cited by 57
Lung-derived soluble mediators are pathogenic in ventilator-induced lung injury
Jaecklin, T., Engelberts, D., Otulakowski, G., O'Brodovich, H. M., Post, M., & Kavanagh, B. P. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00305.2010 · Cited by 52
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
Gaitzsch, E., Passerini, V., Khatamzas, E., Strobl, C. D., Muenchhoff, M., Scherer, C., Osterman, A., Heide, M., Reischer, A., Subklewe, M. S., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000603 · Cited by 55
B Cells in Autoimmune Diabetes
Wong, F. S., & Li, W. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.121 · Cited by 53
CTLA‐4Ig–Induced T Cell Anergy Promotes Wnt‐10b Production and Bone Formation in a Mouse Model
Roser‐Page, S., Vikulina, T., Zayzafoon, M., & Weitzmann, M. N. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38319 · Cited by 52
Leandro, M. J., & de la Torre, I. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03978.x · Cited by 52
Infectious complications of biologic agents.
Martı́n-Mola, E., & Balsa, A. (2009) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2009.03.009 · Cited by 59
Inflammation‐independent defective early B cell tolerance checkpoints in rheumatoid arthritis
Menard, L. C., Samuels, J., Ng, Y.-S., & Meffre, E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30164 · Cited by 52
Rheumatoid Arthritis and Reproduction
Golding, A., Haque, U. J., & Giles, J. T. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.01.001 · Cited by 51
Expression of BAFF and BAFF‐R in the synovial tissue of patients with rheumatoid arthritis
Nakajima, K., Itoh, K., Nagatani, K., Okawa‐Takatsuji, M., Fujii, T., Kuroki, H., Katsuragawa, Y., Aotsuka, S.-I., & Mimori, A. (2007) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740701286615 · Cited by 52
B-cell depletion with rituximab in the treatment of autoimmune diseases
Nielsen, C. H., Fassi, D. E., Hasselbalch, H. C., Bendtzen, K., & Hegedűs, L. D. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.1061 · Cited by 52
Human B Cell Tolerance and Its Failure in Rheumatoid Arthritis
Samuels, J., Ng, Y.-S., Coupillaud, C., Paget, D., & Meffre, E. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.014 · Cited by 52
Rodrı́guez-Valverde, V., Cáliz, R., Álvaro, J. M. Á.-G., de la Fuente, J. L. M., Mendoza, J. M., Molina, J. T., Andreu, J. L., García, F. J. B., Gualda, E. B., Crespillo, J. C., et al. (2006) · Reumatología Clínica · doi:10.1016/s1699-258x(06)73097-2 · Cited by 52
Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome.
Devauchelle‐Pensec, V., Morvan, J., Rat, A., Jousse‐Joulin, S., Pennec, Y., Pers, J.-O., Jamin, C., Renaudineau, Y., Quintin‐Roué, I., Cochener, B., et al. (2011) · PubMed · Cited by 52
Liao, T., Lin, C., Chen, Y., Chang, C.-L., Chen, H., & Chen, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153217 · Cited by 52
Cherukuri, A., Salama, A. D., Carter, C. R., Landsittel, D. P., Arumugakani, G., Clark, B., Rothstein, D. M., & Baker, R. J. (2016) · Kidney International · doi:10.1016/j.kint.2016.08.028 · Cited by 52
Magatti, M., Masserdotti, A., Signoroni, P. B., Vertua, E., Stefani, F. R., Silini, A. R., & Parolini, O. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01156 · Cited by 52
Anti‐CD20 treatment in Primary Sjögren’s Syndrome
Isaksen, K., Jonsson, R., & Omdal, R. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02185.x · Cited by 52
Costimulatory Pathways in Rheumatoid Synovitis and T‐Cell Senescence
Goronzy, J. J., Henel, G., Sawai, H., Singh, K., Lee, E. B., Pryshchep, S., & Weyand, C. M. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.022 · Cited by 52
Díaz‐González, F., Alten, R. H.-E., Bensen, W., Brown, J. P., Sibley, J. T., Dougados, M., Bombardieri, S., Durez, P., Ortiz, P., de-Miquel, G., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062554 · Cited by 52
Lakos, G., Soós, L., Fekete, A., Szabo, Z., Zeher, M., Horváth, I. F., Dankó, K., Kapitány, A., Gyetvai, Á., Szegedi, G., et al. (2008) · PubMed · Cited by 52
Xue, C., Yang, B., Xu, J., Zhou, C., Zhang, L., Gao, X., Dai, B., Yu, S., Mao, Z., Mei, C., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa191 · Cited by 51
Double-negative-2 B cells are the major synovial plasma cell precursor in rheumatoid arthritis
Wing, E., Sutherland, C., Miles, K., Gray, D., Goodyear, C. S., Otto, T. D., Breusch, S. J., Cowan, G. J. M., & Gray, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241474 · Cited by 51
Advances in the treatment of coeliac disease: an immunopathogenic perspective
Kaukinen, K., Lindfors, K., & Mäki, M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.141 · Cited by 51
B Cell Depletion Enhances T Regulatory Cell Activity Essential in the Suppression of Arthritis
Hamel, K. M., Cao, Y., Ashaye, S., Wang, Y., Dunn, R., Kehry, M. R., Glant, T. T., & Finnegan, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101844 · Cited by 51
Biomarkers for rheumatoid arthritis: Making it personal
Lindström, T. M., & Robinson, W. H. (2010) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2010.493406 · Cited by 51
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
Bukhari, M. A. S., Abernethy, R., Deighton, C., Ding, T., Hyrich, K. L., Lunt, M., Luqmani, R. A., Kiely, P. D. W., Bosworth, A., Ledingham, J. M., et al. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker106a · Cited by 51
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Reddy, V. R., Dahal, L. N., Cragg, M. S., & Leandro, M. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.009 · Cited by 51
Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406
Zhu, Y., Herlaar, E., Masuda, E. S., Burleson, G. R., Nelson, A. J., Grossbard, E. B., & Clemens, G. R. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.03.027 · Cited by 51
Morbach, H., Wiegering, V. A., Richl, P., Schwarz, T., Suffa, N., Eichhorn, E.-M., Eyrich, M. K., & Girschick, H. J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30569 · Cited by 51
Silverman, G. J., & Boyle, D. L. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00627.x · Cited by 51
Teng, Y. K. O., Wheater, G., Hogan, V. E., Stocks, P., Levarht, E. N., Huizinga, T. W. J., Toes, R. E. M., & van Laar, J. M. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3770 · Cited by 51
Tamimoto, Y., Horiuchi, T., Tsukamoto, H., Otsuka, J., Mitoma, H., Kimoto, Y., Nakashima, H., Muta, K., Abe, Y., Kiyohara, C., et al. (2008) · Lara D. Veeken · doi:10.1093/rheumatology/ken071 · Cited by 51
Singh, N., Madhira, V., Hu, C., Olex, A. L., Bergquist, T. R., Fitzgerald, K. C., Huling, J. D., Patel, R. C., & Singh, J. A. (2022) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2022.152149 · Cited by 50
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
